JP2013517286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013517286A5 JP2013517286A5 JP2012549107A JP2012549107A JP2013517286A5 JP 2013517286 A5 JP2013517286 A5 JP 2013517286A5 JP 2012549107 A JP2012549107 A JP 2012549107A JP 2012549107 A JP2012549107 A JP 2012549107A JP 2013517286 A5 JP2013517286 A5 JP 2013517286A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- membered
- alkyl
- substituted
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 methylcyclohexyl Chemical group 0.000 claims description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- 125000000623 heterocyclic group Chemical group 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 45
- 125000001072 heteroaryl group Chemical group 0.000 claims description 41
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 239000003112 inhibitor Substances 0.000 claims description 28
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims description 8
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 8
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 8
- 239000002777 nucleoside Substances 0.000 claims description 8
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 230000009385 viral infection Effects 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 claims description 4
- 229940123073 Angiotensin antagonist Drugs 0.000 claims description 4
- 101001023866 Arabidopsis thaliana Mannosyl-oligosaccharide glucosidase GCS1 Proteins 0.000 claims description 4
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 claims description 4
- 241000710781 Flaviviridae Species 0.000 claims description 4
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 claims description 4
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 101800001014 Non-structural protein 5A Proteins 0.000 claims description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000134 cyclophilin inhibitor Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 229960000329 ribavirin Drugs 0.000 claims description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims description 4
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 3
- 241000711549 Hepacivirus C Species 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims description 2
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims description 2
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims description 2
- 241000725619 Dengue virus Species 0.000 claims description 2
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 2
- 241000710912 Kunjin virus Species 0.000 claims description 2
- 241000725177 Omsk hemorrhagic fever virus Species 0.000 claims description 2
- 241000710888 St. Louis encephalitis virus Species 0.000 claims description 2
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims description 2
- 241000710886 West Nile virus Species 0.000 claims description 2
- 241000710772 Yellow fever virus Species 0.000 claims description 2
- 241000907316 Zika virus Species 0.000 claims description 2
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- 125000004956 cyclohexylene group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 229940051021 yellow-fever virus Drugs 0.000 claims description 2
- 230000003510 anti-fibrotic effect Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 description 17
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 16
- 125000003342 alkenyl group Chemical group 0.000 description 16
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 11
- 125000004104 aryloxy group Chemical group 0.000 description 10
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000005133 alkynyloxy group Chemical group 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 125000003302 alkenyloxy group Chemical group 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 3
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 2
- 0 *C(N(*)c1c(C(O)=O)[s]c(C#C*)c1)=O Chemical compound *C(N(*)c1c(C(O)=O)[s]c(C#C*)c1)=O 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000004419 alkynylene group Chemical group 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 125000004641 (C1-C12) haloalkyl group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 description 1
- LIEYPKBEPJTWBV-ZECKAXTISA-O CC(C)(C)C#Cc1cc(N([C@H](CC2)CC/C2=[NH+]/OCc2ccccc2)C(C2CCC3(CC3)CC2)=O)c(C(O)=O)[s]1 Chemical compound CC(C)(C)C#Cc1cc(N([C@H](CC2)CC/C2=[NH+]/OCc2ccccc2)C(C2CCC3(CC3)CC2)=O)c(C(O)=O)[s]1 LIEYPKBEPJTWBV-ZECKAXTISA-O 0.000 description 1
- QSBRMGIXSIHKNL-UHFFFAOYSA-N CC(CC1)CCC1C(N(C(C1)=C2SC1C#CC(C)(C)C)N(c1ccccn1)OC2O)=O Chemical compound CC(CC1)CCC1C(N(C(C1)=C2SC1C#CC(C)(C)C)N(c1ccccn1)OC2O)=O QSBRMGIXSIHKNL-UHFFFAOYSA-N 0.000 description 1
- DVYWQKGHPWBWRE-UUNIZHOLSA-N CC(CC1)CCC1C(N([C@H](CC1)CC[C@@H]1NN(C)c1ncccc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound CC(CC1)CCC1C(N([C@H](CC1)CC[C@@H]1NN(C)c1ncccc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O DVYWQKGHPWBWRE-UUNIZHOLSA-N 0.000 description 1
- DVYWQKGHPWBWRE-ULBZPVTCSA-N CC(CC1)CCC1C(N([C@H](CC1)CC[C@H]1NN(C)c1ncccc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound CC(CC1)CCC1C(N([C@H](CC1)CC[C@H]1NN(C)c1ncccc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O DVYWQKGHPWBWRE-ULBZPVTCSA-N 0.000 description 1
- BBUPOXQSCIUXSZ-UHFFFAOYSA-N CC(CC1)CCC1C(N(c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)N(C)C)O Chemical compound CC(CC1)CCC1C(N(c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)N(C)C)O BBUPOXQSCIUXSZ-UHFFFAOYSA-N 0.000 description 1
- CIMPAUUBCFCROW-UHFFFAOYSA-N CC(CC1)CCC1C(N(c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)N(C)CC1CCOCC1)=O Chemical compound CC(CC1)CCC1C(N(c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)N(C)CC1CCOCC1)=O CIMPAUUBCFCROW-UHFFFAOYSA-N 0.000 description 1
- QSQOBEWNOVYBRN-MQZTZHRLSA-N C[C@H](CC1)CC[C@@H]1C(N(C(CC1)CCC1NC(OC(CC1)CCN1C(OC(C)(C)C)=O)=C)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N(C(CC1)CCC1NC(OC(CC1)CCN1C(OC(C)(C)C)=O)=C)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O QSQOBEWNOVYBRN-MQZTZHRLSA-N 0.000 description 1
- 241000282816 Giraffa camelopardalis Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- SEBVTXISLUOJJA-UHFFFAOYSA-N OCC(C1)C11C2(CC2)OCC11CC1 Chemical compound OCC(C1)C11C2(CC2)OCC11CC1 SEBVTXISLUOJJA-UHFFFAOYSA-N 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29557610P | 2010-01-15 | 2010-01-15 | |
| US61/295,576 | 2010-01-15 | ||
| PCT/US2011/021279 WO2011088303A1 (en) | 2010-01-15 | 2011-01-14 | Inhibitors of flaviviridae viruses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013517286A JP2013517286A (ja) | 2013-05-16 |
| JP2013517286A5 true JP2013517286A5 (enExample) | 2014-02-20 |
| JP5777223B2 JP5777223B2 (ja) | 2015-09-09 |
Family
ID=43827460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012549107A Active JP5777223B2 (ja) | 2010-01-15 | 2011-01-14 | フラビウイルス科ウイルスのインヒビター |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8524764B2 (enExample) |
| EP (1) | EP2523951B1 (enExample) |
| JP (1) | JP5777223B2 (enExample) |
| KR (1) | KR20120123678A (enExample) |
| CN (1) | CN102712632A (enExample) |
| AP (1) | AP2012006413A0 (enExample) |
| AU (1) | AU2011205797B2 (enExample) |
| BR (1) | BR112012017402A2 (enExample) |
| CA (1) | CA2785563C (enExample) |
| CL (1) | CL2012001959A1 (enExample) |
| CO (1) | CO6561783A2 (enExample) |
| CR (1) | CR20120418A (enExample) |
| EA (1) | EA201290575A1 (enExample) |
| EC (1) | ECSP12012103A (enExample) |
| ES (1) | ES2543105T3 (enExample) |
| MX (1) | MX2012008221A (enExample) |
| NZ (1) | NZ600816A (enExample) |
| PE (1) | PE20121522A1 (enExample) |
| PT (1) | PT2523951E (enExample) |
| SG (1) | SG182478A1 (enExample) |
| UA (1) | UA108221C2 (enExample) |
| WO (1) | WO2011088303A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010276441B2 (en) * | 2009-07-21 | 2015-07-02 | Gilead Sciences, Inc. | Inhibitors of Flaviviridae viruses |
| JP5774008B2 (ja) | 2009-09-09 | 2015-09-02 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｌａｖｉｖｉｒｉｄａｅウイルスの阻害剤 |
| AP3576A (en) | 2010-01-15 | 2016-02-08 | Gilead Sciences Inc | Inhibitors of flaviviridae viruses |
| UA108221C2 (uk) | 2010-01-15 | 2015-04-10 | Похідні тіофен-2-карбонової кислоти як інгібітори вірусів flaviviridae | |
| PT2734515E (pt) | 2011-07-13 | 2016-03-11 | Gilead Sciences Inc | Derivados de ácido tiofen-2-carboxílico úteis como inibidores de vírus flaviviridae |
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| US8759544B2 (en) | 2012-08-17 | 2014-06-24 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
| US8841340B2 (en) | 2012-08-17 | 2014-09-23 | Gilead Sciences, Inc. | Solid forms of an antiviral compound |
| US8927741B2 (en) | 2012-08-17 | 2015-01-06 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
| CA2958022A1 (en) * | 2014-10-01 | 2016-04-07 | Janssen Pharmaceuticals, Inc | Mono- or di-substituted indoles as dengue viral replication inhibitors |
| US10190162B2 (en) | 2014-10-23 | 2019-01-29 | Complete Genomics, Inc. | Signal confinement sequencing (SCS) and nucleotide analogues for signal confinement sequencing |
| HRP20211456T1 (hr) | 2014-12-26 | 2021-12-24 | Emory University | Protuvirusni derivati n4-hidroksicitidina |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| US10913716B2 (en) | 2016-03-31 | 2021-02-09 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| SG11201808138YA (en) | 2016-03-31 | 2018-10-30 | Janssen Pharmaceuticals Inc | Substituted indole derivatives as dengue viral replication inhibitors |
| CR20180494A (es) | 2016-04-01 | 2019-01-29 | Janssen Pharmaceuticals Inc | Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| EA039702B1 (ru) | 2017-05-22 | 2022-03-01 | Янссен Фармасьютикалз, Инк. | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге |
| KR102625988B1 (ko) | 2017-05-22 | 2024-01-16 | 얀센 파마슈티칼즈, 인코포레이티드 | 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체 |
| EP3641762A4 (en) | 2017-06-20 | 2021-03-10 | C4 Therapeutics, Inc. | N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION |
| SG11202004403QA (en) | 2017-12-07 | 2020-06-29 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861421A (en) | 1995-12-21 | 1999-01-19 | Smithkline Beecham Corporation | 4,4-(disubstituted) cyclohexan-1-one monomers and related compounds |
| US20050119332A1 (en) * | 1998-03-12 | 2005-06-02 | Lone Jeppesen | Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases) |
| US20020002199A1 (en) * | 1998-03-12 | 2002-01-03 | Lone Jeppesen | Modulators of protein tyrosine phosphatases (ptpases) |
| EP1401825B1 (en) * | 2001-06-11 | 2009-08-05 | Virochem Pharma Inc. | Thiophene derivatives as antiviral agents for flavivirus infection |
| WO2002100846A1 (en) | 2001-06-11 | 2002-12-19 | Shire Biochem Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| AU2003291885A1 (en) | 2002-12-10 | 2004-06-30 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| DE60332482D1 (de) * | 2002-12-10 | 2010-06-17 | Virochem Pharma Inc | Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen |
| DE10359791A1 (de) * | 2003-12-19 | 2005-07-21 | Bayer Healthcare Ag | Substituierte Thiophene |
| WO2005081954A2 (en) * | 2004-02-25 | 2005-09-09 | Wyeth | Inhibitors of protein tyrosine phosphatase 1b |
| MXPA06010520A (es) * | 2004-03-30 | 2007-03-26 | Chiron Corp | Derivados de tiofeno sustituidos como agentes anticancerosos. |
| DE102005028077A1 (de) * | 2004-12-22 | 2006-07-13 | Aicuris Gmbh & Co. Kg | Alkinyl-substituierte Thiophene |
| DE102004061746A1 (de) | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Alkinyl-substituierte Thiophene |
| SG161315A1 (en) * | 2005-05-13 | 2010-05-27 | Virochem Pharma Inc | Compounds and methods for the treatment or prevention of flavivirus infections |
| CN101384605A (zh) | 2006-02-15 | 2009-03-11 | 塞诺菲-安万特股份有限公司 | 新的氨基醇取代的芳基噻吩并嘧啶酮、其制备方法以及其作为药物的用途 |
| NZ596922A (en) * | 2006-11-15 | 2013-03-28 | Virochem Pharma Inc | Thiophene analogues for the treatment or prevention of Flavivirus infections |
| US20090274655A1 (en) * | 2006-11-17 | 2009-11-05 | Richard Martin Grimes | 2-carboxy thiophene derivatives as anti viral agents |
| JP2012510525A (ja) | 2008-12-03 | 2012-05-10 | プレシディオ ファーマシューティカルズ インコーポレイテッド | Ｈｃｖｎｓ５ａの阻害剤 |
| AU2010276441B2 (en) | 2009-07-21 | 2015-07-02 | Gilead Sciences, Inc. | Inhibitors of Flaviviridae viruses |
| JP5774008B2 (ja) | 2009-09-09 | 2015-09-02 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｌａｖｉｖｉｒｉｄａｅウイルスの阻害剤 |
| CA2781614A1 (en) | 2009-11-25 | 2011-06-09 | Vertex Pharmaceuticals Incorporated | 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections |
| UA108221C2 (uk) * | 2010-01-15 | 2015-04-10 | Похідні тіофен-2-карбонової кислоти як інгібітори вірусів flaviviridae | |
| AP3576A (en) | 2010-01-15 | 2016-02-08 | Gilead Sciences Inc | Inhibitors of flaviviridae viruses |
| JP2013529684A (ja) * | 2010-06-28 | 2013-07-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染の処置または予防のための化合物および方法 |
| PT2734515E (pt) | 2011-07-13 | 2016-03-11 | Gilead Sciences Inc | Derivados de ácido tiofen-2-carboxílico úteis como inibidores de vírus flaviviridae |
-
2011
- 2011-01-14 UA UAA201208925A patent/UA108221C2/ru unknown
- 2011-01-14 NZ NZ600816A patent/NZ600816A/en not_active IP Right Cessation
- 2011-01-14 WO PCT/US2011/021279 patent/WO2011088303A1/en not_active Ceased
- 2011-01-14 JP JP2012549107A patent/JP5777223B2/ja active Active
- 2011-01-14 EA EA201290575A patent/EA201290575A1/ru unknown
- 2011-01-14 EP EP20110701588 patent/EP2523951B1/en active Active
- 2011-01-14 KR KR1020127021312A patent/KR20120123678A/ko not_active Withdrawn
- 2011-01-14 AP AP2012006413A patent/AP2012006413A0/xx unknown
- 2011-01-14 US US13/006,761 patent/US8524764B2/en active Active
- 2011-01-14 CA CA2785563A patent/CA2785563C/en active Active
- 2011-01-14 PE PE2012001004A patent/PE20121522A1/es not_active Application Discontinuation
- 2011-01-14 ES ES11701588.3T patent/ES2543105T3/es active Active
- 2011-01-14 SG SG2012051215A patent/SG182478A1/en unknown
- 2011-01-14 MX MX2012008221A patent/MX2012008221A/es active IP Right Grant
- 2011-01-14 BR BR112012017402A patent/BR112012017402A2/pt not_active IP Right Cessation
- 2011-01-14 CN CN2011800059739A patent/CN102712632A/zh active Pending
- 2011-01-14 PT PT117015883T patent/PT2523951E/pt unknown
- 2011-01-14 AU AU2011205797A patent/AU2011205797B2/en active Active
-
2012
- 2012-06-29 CO CO12109858A patent/CO6561783A2/es unknown
- 2012-07-13 CL CL2012001959A patent/CL2012001959A1/es unknown
- 2012-08-10 CR CR20120418A patent/CR20120418A/es unknown
- 2012-08-13 EC ECSP12012103 patent/ECSP12012103A/es unknown
-
2013
- 2013-08-02 US US13/958,424 patent/US8884030B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013517286A5 (enExample) | ||
| JP2013517291A5 (enExample) | ||
| JP2012533630A5 (enExample) | ||
| JP5777223B2 (ja) | フラビウイルス科ウイルスのインヒビター | |
| CA2979490C (en) | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor | |
| JP6034883B2 (ja) | ヘテロ三環状部分を有する抗ウイルス性化合物 | |
| JP2014520822A5 (enExample) | ||
| JP2011518835A5 (enExample) | ||
| JP2010539241A5 (enExample) | ||
| TW201136942A (en) | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | |
| JP2011521903A5 (enExample) | ||
| WO2015107495A1 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 | |
| US20090060874A1 (en) | Bicyclic pyrrolidine derivatives | |
| KR20080019213A (ko) | 티아졸 화합물 및 그 사용방법 | |
| JP2016503800A5 (enExample) | ||
| US20170022150A1 (en) | Hepatitis b antiviral agents | |
| JP2013514359A5 (enExample) | ||
| CA3034185A1 (en) | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor | |
| ES2828642T3 (es) | Miméticos Smac para el tratamiento de una infección intracelular persistente de VHB | |
| EP1444225B1 (en) | Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists. | |
| KR101561964B1 (ko) | 옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물 | |
| JP7154659B2 (ja) | 縮合環含有化合物、その使用及びそれを含む医薬組成物 | |
| JP2015526504A (ja) | Ｈｃｖの大環状プロテアーゼ阻害剤と、非ヌクレオシドｈｃｖ阻害剤と、リトナビルとの組み合わせ | |
| JP2015526504A5 (enExample) | ||
| JP7749545B6 (ja) | Ｔｌｒ７作用薬を含む薬物の組み合わせ |